Category: Misc

    • Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player.
    • Rosado MM, Pioli C.
    • Cancers (Basel). 2023 Feb 8;15(4):1093. doi: 10.3390/cancers15041093.

    • Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player.
    • Rosado MM, Pioli C.
    • Cancers (Basel). 2023 Feb 8;15(4):1093. doi: 10.3390/cancers15041093.

    • LitAlert ~~ GeneLit.com

    • Molecular dynamics simulations reveal the effect of mutations in the RING domains of BRCA1-BARD1 complex and its relevance to the prognosis of breast cancer.
    • Kiewhuo K, Priyadarsinee L, Sarma H, Sastry GN.
    • J Biomol Struct Dyn. 2023 Feb 12:1-19. doi: 10.1080/07391102.2023.2175383. Epub ahead of print.

    • Uterine Cavity Lavage Mutation Analysis in Lithuanian Ovarian Cancer Patients.
    • Žilovic D, Vaicekauskaite I, Ciurliene R, Sabaliauskaite R, Jarmalaite S.
    • Cancers (Basel). 2023 Jan 30;15(3):868. doi: 10.3390/cancers15030868.

    • LitAlert ~~ GeneLit.com

    • Design, Synthesis, and Evaluation of 1H-benzo[d]imidazole-4-carboxamide PARP-1 Inhibitors Using Different Saturated Nitrogen-Contained Heterocycle as linker Group.
    • Wu K, Peng X, Li Y, Chen M, Liu Y, Dan L, Jiang L, Yan H, Junmei P, Cao X.
    • Chem Biol Drug Des. 2023 Feb 8. doi: 10.1111/cbdd.14216. Epub ahead of print.

    • PARylation of BRCA1 limits DNA break resection through BRCA2 and EXO1.
    • Lodovichi S, Quadri R, Sertic S, Pellicioli A.
    • Cell Rep. 2023 Feb 1;42(2):112060. doi: 10.1016/j.celrep.2023.112060. Epub ahead of print.

    • BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity.
    • Wu B, Qi L, Chiang HC, Pan H, Zhang X, Greenbaum A, Stark E, Wang LJ, Chen Y, Haddad BR, Clagett D, Isaacs C, Elledge R, Horvath A, Hu Y, Li R.
    • J Immunother Cancer. 2023 Feb;11(2):e005852. doi: 10.1136/jitc-2022-005852.

    • LitAlert ~~ GeneLit.com

    • Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death.
    • Avelar RA, Armstrong AJ, Carvette G, Gupta R, Puleo N, Colina JA, Joseph P, Sobeck AM, O'Connor CM, Raines B, Gandhi A, Dziubinski ML, Ma DS, Resnick K, Singh S, Zanotti K, Nagel C, Waggoner S, Thomas DG, Skala SL, Zhang J, Narla G, DiFeo A.
    • Mol Cancer Ther. 2023 Feb 14:MCT-21-0880. doi: 10.1158/1535-7163.MCT-21-0880. Epub ahead of print.

    • PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality.
    • Yakovlev V, Sullivan SA, Fields E, Temkin SM.
    • Front Oncol. 2023 Feb 13;13:1124147. doi: 10.3389/fonc.2023.1124147.

    • LitAlert ~~ GeneLit.com

    • Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer.
    • Huang Y, Liu C, You L, Li X, Chen G, Fan J.
    • J Cell Mol Med. 2023 Feb 8. doi: 10.1111/jcmm.17683. Epub ahead of print.

    • Germline cancer gene expression quantitative trait loci are associated with local and global tumor mutations.
    • Liu Y, Gusev A, Kraft P.
    • Cancer Res. 2023 Feb 6:CAN-22-2624. doi: 10.1158/0008-5472.CAN-22-2624. Epub ahead of print.

    • APE2: catalytic function and synthetic lethality draw attention as a cancer therapy target.
    • McMahon A, Zhao J, Yan S.
    • NAR Cancer. 2023 Feb 6;5(1):zcad006. doi: 10.1093/narcan/zcad006.

    • Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305.
    • Zheng J, Li Z, Min W.
    • Front Pharmacol. 2023 Jan 23;13:979873. doi: 10.3389/fphar.2022.979873.

    • LitAlert ~~ GeneLit.com

    • Germline cancer gene expression quantitative trait loci are associated with local and global tumor mutations.
    • Liu Y, Gusev A, Kraft P.
    • Cancer Res. 2023 Feb 6:CAN-22-2624. doi: 10.1158/0008-5472.CAN-22-2624. Epub ahead of print.

    • Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor.
    • Wang S, Xia Y, Huang P, Xu C, Qian Y, Fang T, Gao Q.
    • J Oncol. 2023 Feb 6;2023:1453739. doi: 10.1155/2023/1453739.

    • A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
    • Gao B, Voskoboynik M, Cooper A, Wilkinson K, Hoon S, Hsieh CY, Cai S, Tian YE, Bao J, Ma N, Wang C, Zhang M, Li B, Guo M, Zhou R, Wang X, Xu C, de Souza P.
    • Cancer. 2023 Jan 31. doi: 10.1002/cncr.34662. Epub ahead of print.

    Related:

    •• Identifier: NCT03507543: The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • LitAlert ~~ GeneLit.com

    • LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma.
    • Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, Feng Y, Mendez-Dorantes C, Ippoliti PJ, Hobday S, Mitchell MA, Doberstein K, Gysler SM, Hirsch MS, Schwartz L, Birrer MJ, Skates SJ, Burns KH, Carr SA, Drapkin R.
    • Sci Rep. 2023 Jan 27;13(1):1537. doi: 10.1038/s41598-023-28840-5.

    • Inflammatory cytokines-enriched microenvironment plays key roles for the development of breast cancers.
    • Takeuchi Y, Gotoh N.
    • Cancer Sci. 2023 Jan 26. doi: 10.1111/cas.15734. Epub ahead of print.
    • Review

    • Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency.
    • Guantay L, Garro C, Siri S, Pansa MF, Ghidelli-Disse S, Paviolo N, Racca A, Nicotra V, Radu C, Bocco JL, Felice R, Jansson KH, Remlinger K, Amador A, Stronach E, Coleman K, Muelbaier M, Drewes G, Gloger I, Madauss K, García M, Gottifredi V, Soria G.
    • Drug Resist Updat. 2023 Jan 22;67:100932. doi: 10.1016/j.drup.2023.100932. Epub ahead of print.

    • PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage.
    • Kim C, Wang XD, Jang S, Yu Y.
    • Biochem Biophys Res Commun. 2023 Jan 20;646:78-85. doi: 10.1016/j.bbrc.2023.01.055. Epub ahead of print.

    • Curcumin enhances the anti-cancer efficacy of paclitaxel in ovarian cancer by regulating the miR-9-5p/BRCA1 axis.
    • Liu Y, Shen Z, Zhu T, Lu W, Fu Y.
    • Front Pharmacol. 2023 Jan 10;13:1014933. doi: 10.3389/fphar.2022.1014933.